durable response


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia.

durable response

In cancer care, a long-lasting positive reaction to tumor therapy, usually lasting at least a year.
See also: response
References in periodicals archive ?
Several clinical case studies have reported durable response suppression following a DRO procedure (e.
During the phase three study, which was the basis for the Committee for Medicinal Products for Human Use opinion, Imlygic was claimed to significantly extend the primary endpoint of durable response rates compared with granulocyte-macrophage colony-stimulating factor.
Interferon alfa may be the treatment of choice for a young, highly motivated patient willing to withstand its significant side effects in order to undergo a relatively short course of therapy with a more durable response and a higher rate of hepatitis B surface antigen loss compared with oral adefovir or entecavir therapy.
Herz and associates theorize that idiopathic childhood urethritis is a manifestation of poor relaxation of the pelvic floor, and treating the underlying dysfunctional elimination can lead to a quicker and more durable response.
The humanized antibody, epratuzumab, is being studied in a pivotal clinical trial to treat indolent non-Hodgkin's lymphoma patients who either do not respond, or who do not have a durable response, to the currently available antibody therapy, Rituxan (Rituximab, IDEC/Genentech).
The high and durable response rates seen in this study are particularly notable given that the study enrolled patients regardless of biomarker status.
Secondary endpoints of the trial include durable response rate, defined as complete or partial responses lasting at least 24 weeks, which is being assessed as a novel endpoint in the post-surgical setting of recurrent HGG.
Alefacept has the lowest efficacy against psoriasis, but it gives a particularly durable response in patients who do respond.
Increasing the durable response rate with a frontline therapy that also removes bleomycin from the regimen, represents a major step forward for the Hodgkin lymphoma community.
Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term durable response and eliminating the burden of chronic care.
If this presumption is correct, the strategy would allow for a more durable response to future antiretroviral therapy, Dr.